Estimating The Value Of Pneumococcal Conjugate Vaccination In India: State-level And National-level Analyses | 17915
Epidemiology: Open Access
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Background and aims:
is a leading cause of childhood pneumonia and meningitis morbidity/
mortality in India. Our objective was to project the health and economic benefits of achieving high coverage of pneumococcal
conjugate vaccine (PCV) in India.
We adapted an existing model and synthesized locally available data to estimate the potential impact of PCV in India
and selected states (Bihar, Delhi, Maharashtra, Tamil Nadu) in terms of averting: Deaths/cases, disease costs and productivity
loss for a single year with three theoretical coverage scenarios for PCV (72%, 80%, 90%). Sensitivity analyses were performed
to evaluate the impact of model assumptions.
PCV in India could result in $427 million (range $188.1-$719.3 million) of cost savings to the public sector in a single
year. Up to $2.4 million of these savings is attributable in averting treatment costs and $67.4 million to meningitis-related
productivity loss. Caretaker productivity and transportation costs that could be averted has accounted for $1.2 million in
savings. Averted lost productivity due to premature death represented 83% of these savings at $355.9 million. The greatest
savings to the public sector ($57.4 million) occurred in Bihar where the burden of disease is high, followed by Maharashtra
with $7 million and Delhi with $2.5 million. For the private sector in India, the benefits of achieving 90% of PCV in a single
year result in $1.7 billion savings. For Bihar, Maharashtra and Delhi, savings to the private sector translated into $225 million,
$27.5 million and $10.7 million, respectively.
Achieving high coverage of PCV results in substantial cost savings to the public and private sectors in India.
Tianyang Liu did her MHS in health economics in May 2013 from Johns Hopkins Bloomberg School of Public Health. Right after graduation, she worked as a health
economist in the International Vaccine Access Center, responsible for the project analyzing economic impact of three childhood vaccines in India. Currently, she is
working as a Researcher in the China National Health Development Research Centre, which is attached to the Ministry of Health. As part of her research interest,
she is now focusing on a project analyzing the influenza vaccine uptake among health care workers in hospitals in China.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals